
What happened
Tech firms are scrambling to reduce the threat of AI-driven bioterrorism, as reported by the Financial Times. AI models, already speeding up drug discovery, also carry dual-use risks: information for vaccines could "create a bioweapon," per a Google DeepMind researcher.
Why it matters
An AI safety expert warned of a "'Mythos' moment for AI and Bio," referencing Anthropic's model finding vulnerabilities in most software. Terrorist groups already employ AI, and assessing risks in bioscience is harder than in cybersecurity, with an immunologist warning, "All it will take is one screw-up."
What to watch
The test is whether AI labs’ safeguards can hold, given that bioscience risk is harder to assess than cybersecurity—and that “all it will take is one screw-up.”
Ask the AI about this article →
Summaries like this, in your inbox every morning.
The article highlights a growing concern among tech firms and researchers: AI's dual-use nature in bioscience. While AI accelerates drug discovery, the same capabilities could be misused to create bioweapons. A Google DeepMind researcher noted that vaccine information could also enable bioweapon creation, underscoring the fine line between beneficial and harmful applications. The comparison to Anthropic's model, which can find vulnerabilities in most software, suggests a parallel in bio risks. Experts emphasize that terrorist groups already use AI, and the difficulty of assessing bioscience risks adds urgency. The immunologist's warning, "All it will take is one screw-up," captures the heightened stakes, though specific incidents have not yet occurred. This context suggests that while current safeguards exist, the potential for misuse remains a pressing concern for the industry.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Google DeepMind released the AlphaGenome Atlas, a one-petabyte dataset predicting effects of roughly nine bill…

Anthropic engineer Jacob Coxon resigned, saying AI companies are racing toward self-improving superintelligenc…

Sequoia co-led a $25 million Series A for Cymphony, valuing it above $100 million, to secure AI agents in ente…

Connor Leahy, U.S. Executive Director of nonprofit ControlAI, told TechCrunch's Equity podcast that AI compani…

The OECD's 2025 PISA study found students who never use AI generally outperform AI users in science, after adj…

Jacob Coxon, formerly of OpenAI, quit Anthropic, warning the industry rush to 'self-improving superintelligenc…
